Overview Financials News + Filings IR Vault Key Docs Charts Ownership Insiders
|
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Jun-30-18 | Dec-31-17 | Jun-30-17 | Dec-31-16 |
| | 10-K | 10-K | 10-K | 10-K | 8-K | 10-K | 8-K | 10-K |
| Revenues: |
| Neurology | 284.8 | 235.7 | 287.2 | 279.8 | | 243.2 | | 238.5 |
| Otometrics | 83.6 | 74.9 | 97.0 | 117.2 | | 114.2 | | |
| Newborn Care | 105.0 | 105.0 | 110.9 | 133.9 | | 143.6 | | 143.4 |
| Total revenues | 473.4 | 415.7 | 495.2 | 530.9 | 259.3 | 501.0 | 246.9 | 381.9 |
| Revenue growth [+] | 13.9% | -16.1% | -6.7% | 6.0% | 5.0% | 31.2% | | 1.6% |
| Neurology | 20.8% | -17.9% | 2.7% | 15.1% | | 1.9% | | 0.5% |
| Otometrics | 11.6% | -22.8% | -17.2% | 2.7% | | | | |
| Newborn Care | 0.0% | -5.3% | -17.2% | -6.8% | | 0.2% | | 3.5% |
| Cost of goods sold | 6.7 | 13.2 | 6.9 | 8.9 | 108.3 | 219.8 | 111.5 | 147.0 |
| Gross profit | 466.7 | 402.4 | 488.3 | 522.0 | 151.0 | 281.2 | 135.4 | 234.9 |
| Gross margin | 98.6% | 96.8% | 98.6% | 98.3% | 58.2% | 56.1% | 54.8% | 61.5% |
| Selling, general and administrative [+] | 168.8 | 156.4 | 188.8 | 207.3 | 110.4 | 200.6 | 102.7 | 135.7 |
| Sales and marketing | 116.0 | 107.3 | 129.1 | 136.7 | 69.3 | 126.2 | 62.6 | 84.8 |
| General and administrative | 52.8 | 49.1 | 59.6 | 70.6 | 41.2 | 74.4 | 40.2 | 50.9 |
| Research and development | 56.3 | 61.3 | 58.7 | 61.5 | 31.1 | 51.8 | 26.5 | 33.4 |
| Other operating expenses | 193.0 | 185.9 | 196.6 | 218.0 | 13.3 | 19.2 | 10.5 | 9.0 |
| EBITDA [+] | 59.6 | 11.7 | 59.8 | 46.5 | 9.5 | 39.7 | 6.2 | 73.7 |
| EBITDA growth | 407.8% | -80.4% | 28.5% | 17.1% | 53.7% | -46.1% | | 2.9% |
| EBITDA margin | 12.6% | 2.8% | 12.1% | 8.8% | 3.7% | 7.9% | 2.5% | 19.3% |
| Depreciation | 11.0 | 12.9 | 15.6 | 11.3 | | 10.9 | | 7.9 |
| EBITA | 48.6 | -1.2 | 44.2 | 35.3 | 9.5 | 28.8 | 6.2 | 65.8 |
| EBITA margin | 10.3% | -0.3% | 8.9% | 6.6% | 3.7% | 5.7% | 2.5% | 17.2% |
| Amortization of intangibles | 17.1 | 15.2 | 15.1 | 22.6 | 13.3 | 19.2 | 10.5 | 9.0 |
| EBIT [+] | 31.5 | -16.4 | 29.1 | 12.7 | -3.8 | 9.6 | -4.3 | 56.8 |
| EBIT growth | -292.1% | -156.4% | 129.5% | 31.5% | -12.0% | -83.0% | | 2.1% |
| EBIT margin | 6.6% | -3.9% | 5.9% | 2.4% | -1.5% | 1.9% | -1.7% | 14.9% |
| Non-recurring items | 7.7 | 3.8 | 44.7 | 37.2 | 2.8 | 0.9 | 0.6 | 1.5 |
| Interest expense, net [+] | -0.1 | 0.0 | -0.3 | -0.3 | | -0.4 | | -0.3 |
| Interest expense | 1.9 | 3.7 | 4.9 | 6.8 | | 5.1 | | 0.4 |
| Interest income | 0.1 | 0.0 | 0.3 | 0.3 | | 0.4 | | 0.3 |
| Other income (expense), net [+] | -2.6 | 1.8 | -0.9 | -1.2 | -4.2 | 1.1 | -1.4 | -0.2 |
| Other | | | | | -0.6 | | 0.8 | |
| Pre-tax income | 19.4 | -22.1 | -21.3 | -32.3 | -10.7 | 5.2 | -6.3 | 54.9 |
| Income taxes | 6.2 | -5.5 | -5.6 | -9.3 | -5.0 | 25.4 | -1.6 | 12.3 |
| Tax rate | 31.9% | 24.7% | 26.3% | 28.9% | 46.7% | 494.0% | 25.5% | 22.4% |
| Net income | 13.2 | -16.6 | -15.7 | -22.9 | -5.7 | -20.3 | -4.7 | 42.6 |
| Net margin | 2.8% | -4.0% | -3.2% | -4.3% | -2.2% | -4.1% | -1.9% | 11.2% |
| |
| Basic EPS [+] | $0.39 | ($0.49) | ($0.47) | ($0.69) | ($0.17) | ($0.62) | ($0.14) | $1.31 |
| Growth | -179.1% | 6.4% | -32.9% | 11.2% | 21.1% | -147.5% | | 11.9% |
| Diluted EPS [+] | $0.39 | ($0.49) | ($0.47) | ($0.69) | ($0.17) | ($0.62) | ($0.14) | $1.29 |
| Growth | -178.4% | 6.4% | -32.9% | 11.2% | 21.1% | -148.4% | | 12.9% |
| |
| Shares outstanding (basic) [+] | 33.7 | 33.6 | 33.7 | 33.1 | 32.8 | 32.6 | 32.5 | 32.5 |
| Growth | 0.3% | -0.4% | 1.8% | 1.7% | 0.9% | 0.3% | | 0.3% |
| Shares outstanding (diluted) [+] | 34.0 | 33.6 | 33.7 | 33.1 | 32.8 | 32.6 | 32.5 | 33.1 |
| Growth | 1.2% | -0.4% | 1.8% | 1.7% | 0.9% | -1.5% | | -0.6% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|